Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
ConclusionsGIPI, combining NLR, CRP, and albumin, is the first inflammatory index with a significant prognostic value in patients with mOGJ/GC receiving ICIs. GIPI merits validation in independent cohorts and prospective clinical trials.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology